Immunization with Amyloid-β Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model

Inclusion body myositis (IBM), the most common muscle disease to afflict the elderly, causes slow but progressive degeneration of skeletal muscle and ultimately paralysis. Hallmark pathological features include T-cell mediated inflammatory infiltrates and aberrant accumulations of proteins, including amyloid-β (Aβ), tau, ubiquitinated-proteins, apolipoprotein E, and α-synuclein in skeletal muscle. A large body of work indicates that aberrant Aβ accumulation contributes to the myodegeneration. Here, we investigated whether active immunization to promote clearance of Aβ from affected skeletal muscle fibers mitigates the IBM-like myopathological features as well as motor impairment in a transgenic mouse model. We report that active immunization markedly reduces intracellular Aβ deposits and attenuates the motor impairment compared with untreated mice. Results from our current study indicate that Aβ oligomers contribute to the myopathy process as they were significantly reduced in the affected skeletal muscle from immunized mice. In addition, the anti-Aβ antibodies produced in the immunized mice blocked the toxicity of the Aβ oligomers in vitro, providing a possible key mechanism for the functional recovery. These findings provide support for the hypothesis that Aβ is one of the key pathogenic components in IBM pathology and subsequent skeletal muscle degeneration.

[1]  C. Masters,et al.  Intracellular amyloid formation in muscle cells of Aβ-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification , 2009, Molecular Neurodegeneration.

[2]  W. Engel,et al.  Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains , 2008, Acta Neuropathologica.

[3]  T. Wisniewski,et al.  Amyloid-β immunisation for Alzheimer's disease , 2008, The Lancet Neurology.

[4]  F. LaFerla,et al.  Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase‐3β , 2008, Annals of neurology.

[5]  M. Dalakas,et al.  Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle , 2008, Brain : a journal of neurology.

[6]  F. Mastaglia,et al.  Sporadic inclusion body myositis: a continuing puzzle , 2008, Neuromuscular Disorders.

[7]  Sara E. Miller,et al.  Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. , 2007, Human molecular genetics.

[8]  I. Nonaka,et al.  A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. , 2007, Human molecular genetics.

[9]  F. LaFerla,et al.  Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles* , 2006, Journal of Biological Chemistry.

[10]  W. Engel,et al.  AβPP-overexpression and proteasome inhibition increase αB-crystallin in cultured human muscle: Relevance to inclusion-body myositis , 2006, Neuromuscular Disorders.

[11]  M. Dalakas,et al.  Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies , 2006, Nature Clinical Practice Neurology.

[12]  B. Kriem,et al.  Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway , 2006, Neurobiology of Disease.

[13]  Anna Fidziańska,et al.  Rimmed vacuoles with beta-amyloid and tau protein deposits in the muscle of children with hereditary myopathy , 2006, Acta Neuropathologica.

[14]  H. Weiner,et al.  Aβ-induced meningoencephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Aβ in a mouse model of Alzheimer's disease , 2006 .

[15]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[16]  Marinos C. Dalakas,et al.  Inflammatory, immune, and viral aspects of inclusion-body myositis , 2006, Neurology.

[17]  W. Klein,et al.  Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.

[18]  H. Weiner,et al.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. , 2005, The Journal of clinical investigation.

[19]  W. Engel,et al.  Molecular pathology and pathogenesis of inclusion‐body myositis , 2005, Microscopy research and technique.

[20]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[21]  Ian Parker,et al.  Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦ , 2005, Journal of Biological Chemistry.

[22]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[23]  Randomized pilot trial of high-dose βINF-1a in patients with inclusion body myositis , 2004, Neurology.

[24]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[25]  Isidro Ferrer,et al.  Proteasomal Expression, Induction of Immunoproteasome Subunits, and Local MHC Class I Presentation in Myofibrillar Myopathy and Inclusion Body Myositis , 2004, Journal of neuropathology and experimental neurology.

[26]  A. Pestronk,et al.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.

[27]  P. Lansbury,et al.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.

[28]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  V. Askanas,et al.  Cystatin C colocalizes with amyloid‐β and coimmunoprecipitates with amyloid‐β precursor protein in sporadic inclusion‐body myositis muscles , 2003 .

[30]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[31]  C. Cotman,et al.  Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. , 2003, International immunology.

[32]  J. Crabbe,et al.  Assessment of genetic susceptibility to ethanol intoxication in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Julio C. Echegoyen,et al.  Inclusion body myositis-like phenotype induced by transgenic overexpression of βAPP in skeletal muscle , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K J Felice,et al.  A pilot randomized trial of oxandrolone in inclusion body myositis , 2002, Neurology.

[35]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[36]  G. Tate,et al.  Hereditary motor and sensory neuropathy with minifascicle formation in a patient with 46XY pure gonadal dysgenesis: A new clinical entity , 2002, Annals of neurology.

[37]  N. Niikawa,et al.  Nonaka myopathy is caused by mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase gene (GNE) , 2002, Journal of Human Genetics.

[38]  Tsviya Olender,et al.  The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy , 2001, Nature Genetics.

[39]  Michael J. Rowan,et al.  Amyloid-β oligomers: their production, toxicity and therapeutic inhibition , 2001 .

[40]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Kenneth M. Rosen,et al.  β-Amyloid Peptide Expression Is Sufficient for Myotube Death: Implications for Human Inclusion Body Myopathy , 2001, Molecular and Cellular Neuroscience.

[42]  S. Spector,et al.  A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM , 2001, Neurology.

[43]  N. Darín,et al.  Autosomal dominant myopathy: missense mutation (Glu-706 --> Lys) in the myosin heavy chain IIa gene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Kristi Kincaid,et al.  M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.

[45]  J. Crabbe,et al.  Sensitivity to Ethanol-Induced Motor Incoordination in FAST and SLOW Selectively Bred Mice , 2000, Pharmacology Biochemistry and Behavior.

[46]  Andrew G. Engel,et al.  αB-Crystallin immunolocalization yields new insights into inclusion body myositis , 2000, Neurology.

[47]  J R Lindsey,et al.  Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. , 1998, The American journal of pathology.

[48]  George M. Martin,et al.  Transgenic Mice Over-Expressing the C-99 Fragment of βPP with an α-Secretase Site Mutation Develop a Myopathy Similar to Human Inclusion Body Myositis , 1998 .

[49]  W. Engel,et al.  Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: relevance to inclusion‐body myopathies , 1998, Neuroreport.

[50]  B. Heyman,et al.  Impaired antibody responses in H-2Ab mice. , 1998, Journal of immunology.

[51]  Xudong Huang,et al.  Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis* , 1998, The Journal of Biological Chemistry.

[52]  W. Engel,et al.  β‐Amyloid precursor epitopes in muscle fibers of inclusion body myositis , 1993 .

[53]  K. Beyreuther,et al.  Amyloidogenicity of rodent and human βA4 sequences , 1993 .

[54]  W. Engel,et al.  beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. , 1993, Neuroreport.

[55]  D. Selkoe,et al.  Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. , 1992, Biochemistry.

[56]  W. Engel,et al.  Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy , 1991, Neuroscience Letters.

[57]  H. Weiner,et al.  Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[58]  F. LaFerla,et al.  Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. , 2006, The American journal of pathology.

[59]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[60]  W. Klein,et al.  Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. , 2006, The Journal of biological chemistry.

[61]  E. Masliah,et al.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.

[62]  W. Engel,et al.  Cystatin C colocalizes with amyloid-beta and coimmunoprecipitates with amyloid-beta precursor protein in sporadic inclusion-body myositis muscles. , 2003, Journal of neurochemistry.

[63]  M. Rowan,et al.  Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. , 2002, Biochemical Society transactions.

[64]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Toepfer,et al.  High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study , 2000, Journal of Neurology.

[66]  B. Banwell,et al.  AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. , 2000, Neurology.

[67]  G. Martin,et al.  Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. , 1998, The American journal of pathology.

[68]  R. Locksley,et al.  The regulation of immunity to Leishmania major. , 1995, Annual review of immunology.

[69]  D. Selkoe,et al.  Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. , 1994, The American journal of pathology.

[70]  K. Beyreuther,et al.  Amyloidogenicity of rodent and human beta A4 sequences. , 1993, FEBS letters.

[71]  H. Mantsch,et al.  Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. , 1993, European journal of biochemistry.

[72]  W. Engel,et al.  beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. , 1993, Annals of neurology.

[73]  Transgenic expression of (cid:1) -APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology , 2022 .